T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$2.57B |
| 2 |
GE Aerospace
GE
|
+$1.8B |
| 3 |
UnitedHealth
UNH
|
+$1.63B |
| 4 |
Marriott International
MAR
|
+$1.62B |
| 5 |
Apple
AAPL
|
+$1.3B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.87B |
| 2 |
JPMorgan Chase
JPM
|
+$1.64B |
| 3 |
Nike
NKE
|
+$1.59B |
| 4 |
Becton Dickinson
BDX
|
+$1.46B |
| 5 |
Alibaba
BABA
|
+$1.32B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
901
Phreesia
PHR
$780M
| $35M | 0.01% |
1,665,915
+460,301
| +38% | +$12.6M |
|
|
ICPT
902
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $34.6M | 0.01% |
548,882
-100,102
| -15% | -$9M |
|
903
Tetra Tech
TTEK
$9.33B
| $34.4M | 0.01% |
2,433,420
+258,080
| +12% | +$4.4M |
|
904
Alcoa
AA
$13.1B
| $34.3M | 0.01% |
5,574,374
+5,505,519
| +7,996% | +$75.6M |
|
905
i3 Verticals
IIIV
$325M
| $34.3M | 0.01% |
1,796,307
+150,064
| +9% | +$4.22M |
|
906
Employers Holdings
EIG
$871M
| $34.3M | 0.01% |
845,698
+564
| +0.1% | +$23.1K |
|
907
Federal Signal
FSS
$7.51B
| $34.1M | 0.01% |
1,249,507
+713,966
| +133% | +$22.2M |
|
908
Zymeworks
ZYME
$1.83B
| $34.1M | 0.01% |
960,406
+85,843
| +10% | +$3.51M |
|
909
Frontdoor
FTDR
$5.83B
| $33.7M | 0.01% |
969,119
-21,877
| -2% | -$931K |
|
910
CMS Energy
CMS
$22.1B
| $33.6M | 0.01% |
571,489
+41,219
| +8% | +$2.64M |
|
|
APLS
911
DELISTED
Apellis Pharmaceuticals
APLS
| $33.5M | 0.01% |
1,250,870
+459,207
| +58% | +$16.3M |
|
912
International Seaways
INSW
$4.71B
| $33.2M | 0.01% |
1,389,158
+234,785
| +20% | +$5.34M |
|
913
Nasdaq
NDAQ
$54.6B
| $33.1M | 0.01% |
1,044,375
-109,236
| -9% | -$3.87M |
|
914
XPO
XPO
$24.7B
| $33M | 0.01% |
1,956,540
+19,578
| +1% | +$523K |
|
915
Manhattan Associates
MANH
$11.7B
| $33M | 0.01% |
662,089
+2,131
| +0.3% | +$154K |
|
916
Onto Innovation
ONTO
$20.6B
| $32.9M | 0.01% |
1,109,555
-67,301
| -6% | -$2.3M |
|
|
ORTX
917
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $32.8M | 0.01% |
435,670
-111,276
| -20% | -$12.8M |
|
918
Novartis
NVS
$288B
| $32.7M | 0.01% |
396,716
+304,665
| +331% | +$27.2M |
|
919
Schrodinger
SDGR
$1.38B
| $32.6M | 0.01% |
+755,085
| New | +$28.5M |
|
920
Hormel Foods
HRL
$13.4B
| $32.3M | 0.01% |
692,208
+39,824
| +6% | +$1.81M |
|
|
RST
921
DELISTED
ROSETTA STONE INC
RST
| $32.1M | 0.01% |
2,291,832
+94,558
| +4% | +$1.59M |
|
|
CMO
922
DELISTED
Capstead Mortgage Corp.
CMO
| $32M | 0.01% |
7,626,956
+87,049
| +1% | +$621K |
|
923
Huntsman Corp
HUN
$1.81B
| $31.8M | 0.01% |
2,204,528
+2,086,102
| +1,762% | +$40.7M |
|
|
EFOR
924
Everforth Inc
EFOR
$1.37B
| $31.7M | 0.01% |
898,819
-121,777
| -12% | -$6.9M |
|
925
Tandem Diabetes Care
TNDM
$1.61B
| $31.7M | 0.01% |
493,159
+236,324
| +92% | +$16.6M |
|
Similar funds
T. Rowe Price Associates's Q1 2020 Portfolio in Review
As of Q1 2020, T. Rowe Price Associates held 2,612 positions worth $632B, down 18% from $771B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2020 filing shows 87 new, 1,525 increased, 823 reduced and 103 closed positions. Its largest new stake was Philips: 33,363,001 shares worth $1.07B. The largest sale was Boeing, an estimated $2.87B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2020 buy was Philips: 33,363,001 shares worth $1.07B.
- T. Rowe Price Associates added most to Humana in Q1 2020, an estimated $2.57B increase.
- T. Rowe Price Associates's biggest Q1 2020 reduction was Boeing, cutting an estimated $2.87B.
- T. Rowe Price Associates fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $846M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $632B portfolio in Q1 2020.
- T. Rowe Price Associates opened 87 new positions and closed 103 in Q1 2020.
- T. Rowe Price Associates's portfolio value fell 18% quarter-over-quarter to $632B.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.